Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...
Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...
Regeneron (REGN) Pharmaceuticals announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology, ASH, 2024 Annual Meeting, taking ...
Medpage Today on MSN5d
Slow Start for AI-Assisted Screening for Diabetic Retinopathy Despite PromiseAccording to Parikh, diabetic retinopathy is the leading cause of blindness and severe vision loss among working-age people ...
Medpage Today on MSN6d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 YearsSAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) will webcast management participation as follows: • Jefferies London Healthcare Conference at 11:00 a.m. BST (6:00 a.m. ET) on ...
Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he ...
Over the summer, BioNTech released Phase 2 data on its mRNA cancer vaccine in the works alongside Regeneron. The vaccine, ...
The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback